4.7 Meeting Abstract

Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 16, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Keywords

-

Categories

Funding

  1. Region Stockholm
  2. Cancer Research KI
  3. Swedish Cancer Society
  4. Swedish Research Council
  5. Roche Sweden

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available